Simvastatin and Panitumumab in Treating Patients With Advanced or Metastatic Colorectal Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

46 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RATIONALE: Simvastatin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as panitumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving simvastatin together with panitumumab may kill more tumor cells.

PURPOSE: This phase II trial is studying how well simvastatin given together with panitumumab works in treating patients with advanced or metastatic colorectal cancer.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

OBJECTIVES:

Primary

* To determine if the proportion (at least 40%) of patients with K-ras mutant-type advanced or metastatic colorectal cancer are free from progression and alive based on RECIST criteria version 1.1 at 11 weeks after the first administration of panitumumab (i.e., 12.5 weeks after the scan at baseline at start of simvastatin).
* To determine if these results are comparable with historical results of k-ras wild-type colorectal carcinoma patients treated with panitumumab.
* To evaluate clinical signs of progression (according to RECIST criteria) in patients treated with this regimen.

Secondary

* To evaluate the safety of this regimen in these patients who have failed prior treatment with fluorouracil-, oxaliplatin-, and irinotecan-containing regimens.
* To evaluate the overall survival of patients who are treated with this regimen and have failed prior fluorouracil-, oxaliplatin-, and irinotecan-containing regimens.
* To evaluate the progression-free survival (based on RECIST criteria version 1.1) of these patients.
* To evaluate the objective response rate (based on RECIST criteria version 1.1) in these patients.
* To evaluate the correlation between skin toxicity and anti-tumor response in these patients.

Tertiary (exploratory)

* To evaluate the role of serum cholesterol as a biomarker during treatment with panitumumab and simvastatin.
* To correlate levels of serum cholesterol with treatment response and other factors, until progression of disease occurs.
* To investigate whether PTEN, PIK3CA, b-raf, ERK, and MEK status correlate with response to panitumumab in these patients.
* To investigate the role of single nucleotide polymorphisms related to the efficacy and metabolism of panitumumab as a predictor for response to panitumumab.
* To investigate the role of proteomics (e.g., EGF) as potential predictive markers for response to panitumumab and as potential biomarkers during treatment with panitumumab.

OUTLINE: This is a multicenter study.

Patients receive oral simvastatin once daily on days 1-14 and panitumumab IV over 30-90 minutes on day 1. Treatment repeats every 2 weeks in the absence of disease progression or unacceptable toxicity.

Blood samples are collected periodically for biomarker and other analyses.

After completion of study treatment, patients are followed for 30 days and then every 3 months thereafter.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colorectal Cancer

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

recurrent colon cancer stage III colon cancer stage IV colon cancer recurrent rectal cancer stage III rectal cancer stage IV rectal cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

panitumumab

Intervention Type BIOLOGICAL

simvastatin

Intervention Type DRUG

laboratory biomarker analysis

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

DISEASE CHARACTERISTICS:

* Diagnosis of colorectal cancer

* Advanced or metastatic disease
* Failed prior fluorouracil-, oxaliplatin- and irinotecan-containing regimens

* In case of progressive disease within 6 months after start of adjuvant fluorouracil-, oxaliplatin-, and irinotecan-containing regimens, the adjuvant therapy is considered to be treatment for metastatic disease
* Mutant-type k-ras status (mutation in codon 12, 13, or 61) on tumor material
* Measurable disease according to RECIST criteria version 1.1
* Progressive disease in the past 3 months according to RECIST criteria version 1.1
* No symptomatic brain metastases, defined as any symptoms during the past 6 months

PATIENT CHARACTERISTICS:

* WHO performance status 0-2
* WBC ≥ 2.0 x 10\^9/L
* ANC ≥ 1.5 x 10\^9/L
* Platelet count ≥ 100 x 10\^9/L
* Hemoglobin ≥ 9 g/dL
* Serum bilirubin ≤ 1.5 times upper limit of normal (ULN)
* AST/ALT ≤ 3 times ULN (≤ 5 times ULN in case of liver metastases)
* Creatinine clearance ≥ 60 mL/min
* Magnesium normal
* Calcium normal
* Creatine phosphokinase ≤ 2.5 times ULN
* Not pregnant or nursing
* Not planning to become pregnant within 6 months after the end of study treatment
* Fertile patients must use highly effective contraception during and for 6 months after completion of study therapy
* No noncompliance in previous studies
* No alcohol use \> 4 units/day or unwilling to abstain from use
* No history of interstitial lung disease (e.g., pneumonitis or pulmonary fibrosis) or signs of interstitial lung disease on baseline CT scan
* No clinically significant cardiovascular disease (including myocardial infarction, unstable angina, symptomatic congestive heart failure, or serious uncontrolled cardiac arrhythmia) \< 1 year prior to study
* No symptomatic hypothyroidism
* No history of toxicity during statin use

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics
* No prior EGFr-therapy, including monoclonal antibodies (e.g., panitumumab or cetuximab)
* No concurrent verapamil, amiodarone, or dronedarone or unwilling to abstain from use

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Hans Gelderblom, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Leiden University Medical Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Reinier de Graaf Group - Delft

Delft, , Netherlands

Site Status RECRUITING

Leiden University Medical Center

Leiden, , Netherlands

Site Status RECRUITING

Diaconessenhuis Leiden

Leiden, , Netherlands

Site Status RECRUITING

HagaZiekenhuis - Locatie Leyenburg

The Hague, , Netherlands

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Netherlands

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Contact Person

Role: primary

Contact Person

Role: primary

Contact Person

Role: primary

Contact Person

Role: primary